{"success":true,"data":{"pressRelease":{"id":"4751","rtpr_id":"nGNXb3qJdw","ticker":"CUE","exchange":"NASDAQ","all_tickers":["CUE"],"title":"Cue Biopharma Announces 1-for-30 Reverse Stock Split","author":"Globe Newswire","published_at":"2026-04-22T12:37:18.063Z","article_body":"BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.\n(https://www.globenewswire.com/Tracker?data=kCTnPwFy8mitPnw6MbUuu2UWKRm1fOnJm4ZEoHzPS-LbVZz3BmTo-OQOky1DtoDqtV1Yjd-AC9wzIplL2rzvFFE4F74JSs9sgyWqy_rDk_XCAIPQ5aU3dEvWHC5yXWIVuXYq29OZVm5kkVcg2L7GZsPhCzARBkICqKNXjvBsEFonOOdpik7h5gTVYI7TQEoAql-3Mrkq0ixxmfsMxocPEWUz3PzXIE3wdMMkyw7h1j70n2SZfKVBQ9fYiKq1XDyXFiDpmyB7wn9MJE2YnM3jww==) (Nasdaq:\nCUE), a clinical-stage biopharmaceutical company developing a novel class of\ntherapeutic biologics to selectively engage and modulate disease-specific T\ncells for the treatment of autoimmune and inflammatory diseases, today\nannounced that it will implement a 1-for-30 reverse stock split of the issued\nshares of the company’s common stock, effective at 5:00 p.m. Eastern Time on\nApril 23, 2026.\n\nThe reverse stock split was approved by the company’s stockholders at the\ncompany’s 2026 Annual Meeting of Stockholders held on April 13, 2026 (the\n“Annual Meeting”), with the final ratio subsequently determined by the\ncompany’s Board of Directors. One of the primary goals of the reverse stock\nsplit is to increase the per-share market price of the company’s common\nstock to enable the company to regain compliance with the minimum bid price\nrequirement for continued listing on the Nasdaq Capital Market.\n\nThe company’s common stock is expected to begin trading on a split-adjusted\nbasis when the markets open on April 24, 2026 under the company’s existing\nticker “CUE” with the new CUSIP number 22978P205.\n\nAt the effective time of the reverse stock split, every 30 shares of the\ncompany’s issued and outstanding common stock will be automatically\nreclassified and combined into one share of common stock. This will reduce the\nnumber of outstanding shares of Cue Biopharma’s common stock from\napproximately 97.7 million shares to approximately 3.3 million shares. The\nreverse stock split will not change the number of authorized shares of the\ncompany’s common stock or the par value of the common stock. All outstanding\nstock options and warrants to purchase common stock will be adjusted to\nproportionately reduce the number of shares of common stock issuable upon\nexercise of such stock options and warrants and to proportionately increase\nthe exercise price of such stock options and warrants, pursuant to the terms\nof each security and as described in the company's proxy statement for the\nAnnual Meeting as filed with the Securities and Exchange Commission on March\n16, 2026 (as supplemented, the “Proxy Statement”). In addition, the total\nnumber of shares of common stock available for future grants under the\nCompany’s equity incentive plans will be adjusted and proportionately\ndecreased, in accordance with the respective terms of such plans and as\ndescribed in the Proxy Statement.\n\nNo fractional shares will be issued if, as a result of the reverse stock\nsplit, a stockholder would otherwise become entitled to a fractional share\nbecause the number of shares of common stock they hold before the reverse\nstock split is not evenly divisible by the reverse stock split ratio. Instead,\neach such stockholder will be entitled to receive a cash payment in lieu of a\nfractional share.\n\nComputershare Trust Company, N.A. is acting as the exchange agent and transfer\nagent for the reverse stock split. Stockholders holding their shares\nelectronically are not required to take any action to receive post-split\nshares. Stockholders owning shares through a bank, brokerage firm or other\nnominee will have their positions adjusted to reflect the reverse stock split\nand will receive payment for any fractional shares in accordance with the\nprocesses at their respective bank, brokerage firm or nominee. Additional\ninformation regarding the reverse stock split can be found in the Proxy\nStatement. \n\nAbout Cue Biopharma\nCue Biopharma, a clinical-stage biopharmaceutical company, is developing a\nnovel class of injectable biologics to selectively engage and modulate\ndisease-specific T cells directly within the patient’s body. The company’s\nproprietary platform, Immuno-STAT(®) (Selective Targeting and Alteration of T\ncells) and biologics are designed to harness the curative potential of the\nbody’s intrinsic immune system without the adverse effects of broad systemic\nimmune modulation. CUE-401, the company’s lead autoimmune asset, is designed\nto act mechanistically both as a regulator of proinflammatory mechanisms, and\nas a master switch for regulatory T cell (Treg) differentiation to induce\ntolerance. It is a highly innovative, tolerogenic bifunctional molecule\ncombining a TGF-beta breathing-mask moiety with Cue Biopharma’s clinically\nvalidated interleukin 2 (IL-2) mutein in a single injectable biologic.\n\nHeadquartered in Boston, Massachusetts, we are led by an experienced\nmanagement team with deep expertise in immunology and protein engineering as\nwell as the design and clinical development of protein biologics.\n\nFor more information please visit www.cuebiopharma.com and follow us on X\n(https://www.globenewswire.com/Tracker?data=PiQ7HEoTZUQCzkt5JRNuGYb1YpveIgGgeHxb2HMBGaQrcRZDXALHRvObLP9Fb0waUnEw0r1oOORaZUyuJU0XnXMzxp7rIBMEH2C-xPwvMonZkrceC_Z651CjKT8xInwnKdhGS2P28nYvg2KZKVq6zYO17AsVj2VeyrQT37L25AlvQJAPC-tLCH2AcXIwisbC4F51tRj_a6fO_SFp7h_aqZsFlxSm9PcSGWjnYUkna7g4YyNP-Fc7xqCLAQE5syW8-4LN9ZxbjvO1WcgYdOm4NWsQOnGOFQpv4ICz8EmYJWkwNOvLO9n0w_tSFLwCZgAi00cx0qr779yxFVEa5wje6wZpp1SqdCShCH3Uu1OVx_cmrsGEiRK2hw3xgoxkIwq-GSuxT2NnvhLfXBOPAiReWP9r-qLJSDGHsOqilLhkSvAe_iKIhQMH0avXhemEfBwZUVDbV35B5MjWULs3J0jHkw==) and LinkedIn\n(https://www.globenewswire.com/Tracker?data=kurM3RJ8zD9HXQLKgGE7TNHkqpMzCYDLvQ4qTnv9Q7PvrhjvdaEn6hTi4txf9gzwt8Q6WtK6uf6mXO5mk-EPr5u21Odz-BSGI2Jf-lVaW0HHXLhwuXzDAbdcCwxKQXHKphxYnjRe1m0tk6BJ0oCPvkZLDQpzxSdJjP3DObfQ7emXik667KROHlExLiom9JG1y4vcPQkqcDSwgUmxQsldPjhVcSkMS7oJ_4u6V6NJh72j-DZqi7h_xlg0fBhs0P7o).\n\nForward-Looking Statements \nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Such forward-looking\nstatements include, but are not limited to, those regarding: the reverse stock\nsplit and the timing thereof; the impact of the reverse stock split on\nstockholders and other securityholders; the potential for the company to\nincrease its share price and regain compliance with the Nasdaq continued\nlisting rules; the company’s belief regarding the potential benefits and\napplications of its drug candidates and programs, including the company’s\nplans to further advance its differentiating Immuno-STAT(® )platform and lead\nautoimmune asset, CUE-401; and the company’s business strategies, plans and\nprospects. Forward-looking statements, which are based on certain assumptions\nand describe the company’s future plans, strategies and expectations, can\ngenerally be identified by the use of forward-looking terms such as\n“believe,” “expect,” “may,” “will,” “should,” “would,”\n“could,” “seek,” “intend,” “plan,” “goal,” “project,”\n“estimate,” “anticipate,” “strategy,” “future,” “likely,”\n“promise” or other comparable terms, although not all forward-looking\nstatements contain these identifying words. All statements other than\nstatements of historical facts included in this press release regarding the\ncompany’s strategies, prospects, financial condition, operations, costs,\nplans and objectives are forward-looking statements. Important factors that\ncould cause the company’s actual results and financial condition to differ\nmaterially from those indicated in the forward-looking statements include,\namong others, the company’s ability to maintain its collaboration with\nImmunoScape; the company’s limited operating history, limited cash and a\nhistory of losses; the company’s ability to obtain adequate financing to\nfund its business operations in the near term and successfully remediate its\ncurrent “going concern” determination that it does not have sufficient\ncapital on hand to continue operations beyond the next twelve months; the\ncompany’s ability to achieve profitability; potential setbacks in the\ncompany’s research and development efforts including negative or\ninconclusive results from its preclinical studies or clinical trials or the\ncompany’s ability to replicate in later clinical trials positive results\nfound in preclinical studies and early-stage clinical trials of its product\ncandidates; serious and unexpected drug-related side effects or other safety\nissues experienced by participants in clinical trials; its ability to secure\nrequired U.S. Food and Drug Administration (FDA) or other governmental\napprovals for its product candidates and the breadth of any approved\nindication; adverse effects caused by public health pandemics, including\npossible effects on the company’s operations and clinical trials; delays and\nchanges in regulatory requirements, policy and guidelines including potential\ndelays in submitting required regulatory applications to the FDA; the\ncompany’s reliance on licensors, collaborators, contract research\norganizations, suppliers and other business partners; the company’s ability\nto obtain adequate financing to fund its business operations in the future and\nability to continue as a going concern; the company’s ability to maintain\nand enforce necessary patent and other intellectual property protection;\ncompetitive factors; general economic and market conditions and the other\nrisks and uncertainties described in the Risk Factors and Management's\nDiscussion and Analysis of Financial Condition and Results of Operations\nsections of the company’s most recently filed Annual Report on Form 10-K and\nany subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking\nstatement made by the company in this press release is based only on\ninformation currently available to the company and speaks only as of the date\non which it is made. The company undertakes no obligation to publicly update\nany forward-looking statement, whether written or oral, that may be made from\ntime to time, whether as a result of new information, future developments or\notherwise.\n\nInvestor Contact\nMarie Campinell\nSenior Director, Corporate Communications\nCue Biopharma, Inc.\nmcampinell@cuebio.com \n\nMedia Contact\nJonathan Pappas\nLifeSci Communications\njpappas@lifescicomms.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/10541379-34cc-4869-a26f-fd99feead42a)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXb3qJdw","title":"Cue Biopharma Announces 1-for-30 Reverse Stock Split","author":"Globe Newswire","ticker":"CUE","created":"2026-04-22T12:37:18.063Z","tickers":["CUE"],"exchange":"NASDAQ","article_body":"BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.\n(https://www.globenewswire.com/Tracker?data=kCTnPwFy8mitPnw6MbUuu2UWKRm1fOnJm4ZEoHzPS-LbVZz3BmTo-OQOky1DtoDqtV1Yjd-AC9wzIplL2rzvFFE4F74JSs9sgyWqy_rDk_XCAIPQ5aU3dEvWHC5yXWIVuXYq29OZVm5kkVcg2L7GZsPhCzARBkICqKNXjvBsEFonOOdpik7h5gTVYI7TQEoAql-3Mrkq0ixxmfsMxocPEWUz3PzXIE3wdMMkyw7h1j70n2SZfKVBQ9fYiKq1XDyXFiDpmyB7wn9MJE2YnM3jww==) (Nasdaq:\nCUE), a clinical-stage biopharmaceutical company developing a novel class of\ntherapeutic biologics to selectively engage and modulate disease-specific T\ncells for the treatment of autoimmune and inflammatory diseases, today\nannounced that it will implement a 1-for-30 reverse stock split of the issued\nshares of the company’s common stock, effective at 5:00 p.m. Eastern Time on\nApril 23, 2026.\n\nThe reverse stock split was approved by the company’s stockholders at the\ncompany’s 2026 Annual Meeting of Stockholders held on April 13, 2026 (the\n“Annual Meeting”), with the final ratio subsequently determined by the\ncompany’s Board of Directors. One of the primary goals of the reverse stock\nsplit is to increase the per-share market price of the company’s common\nstock to enable the company to regain compliance with the minimum bid price\nrequirement for continued listing on the Nasdaq Capital Market.\n\nThe company’s common stock is expected to begin trading on a split-adjusted\nbasis when the markets open on April 24, 2026 under the company’s existing\nticker “CUE” with the new CUSIP number 22978P205.\n\nAt the effective time of the reverse stock split, every 30 shares of the\ncompany’s issued and outstanding common stock will be automatically\nreclassified and combined into one share of common stock. This will reduce the\nnumber of outstanding shares of Cue Biopharma’s common stock from\napproximately 97.7 million shares to approximately 3.3 million shares. The\nreverse stock split will not change the number of authorized shares of the\ncompany’s common stock or the par value of the common stock. All outstanding\nstock options and warrants to purchase common stock will be adjusted to\nproportionately reduce the number of shares of common stock issuable upon\nexercise of such stock options and warrants and to proportionately increase\nthe exercise price of such stock options and warrants, pursuant to the terms\nof each security and as described in the company's proxy statement for the\nAnnual Meeting as filed with the Securities and Exchange Commission on March\n16, 2026 (as supplemented, the “Proxy Statement”). In addition, the total\nnumber of shares of common stock available for future grants under the\nCompany’s equity incentive plans will be adjusted and proportionately\ndecreased, in accordance with the respective terms of such plans and as\ndescribed in the Proxy Statement.\n\nNo fractional shares will be issued if, as a result of the reverse stock\nsplit, a stockholder would otherwise become entitled to a fractional share\nbecause the number of shares of common stock they hold before the reverse\nstock split is not evenly divisible by the reverse stock split ratio. Instead,\neach such stockholder will be entitled to receive a cash payment in lieu of a\nfractional share.\n\nComputershare Trust Company, N.A. is acting as the exchange agent and transfer\nagent for the reverse stock split. Stockholders holding their shares\nelectronically are not required to take any action to receive post-split\nshares. Stockholders owning shares through a bank, brokerage firm or other\nnominee will have their positions adjusted to reflect the reverse stock split\nand will receive payment for any fractional shares in accordance with the\nprocesses at their respective bank, brokerage firm or nominee. Additional\ninformation regarding the reverse stock split can be found in the Proxy\nStatement. \n\nAbout Cue Biopharma\nCue Biopharma, a clinical-stage biopharmaceutical company, is developing a\nnovel class of injectable biologics to selectively engage and modulate\ndisease-specific T cells directly within the patient’s body. The company’s\nproprietary platform, Immuno-STAT(®) (Selective Targeting and Alteration of T\ncells) and biologics are designed to harness the curative potential of the\nbody’s intrinsic immune system without the adverse effects of broad systemic\nimmune modulation. CUE-401, the company’s lead autoimmune asset, is designed\nto act mechanistically both as a regulator of proinflammatory mechanisms, and\nas a master switch for regulatory T cell (Treg) differentiation to induce\ntolerance. It is a highly innovative, tolerogenic bifunctional molecule\ncombining a TGF-beta breathing-mask moiety with Cue Biopharma’s clinically\nvalidated interleukin 2 (IL-2) mutein in a single injectable biologic.\n\nHeadquartered in Boston, Massachusetts, we are led by an experienced\nmanagement team with deep expertise in immunology and protein engineering as\nwell as the design and clinical development of protein biologics.\n\nFor more information please visit www.cuebiopharma.com and follow us on X\n(https://www.globenewswire.com/Tracker?data=PiQ7HEoTZUQCzkt5JRNuGYb1YpveIgGgeHxb2HMBGaQrcRZDXALHRvObLP9Fb0waUnEw0r1oOORaZUyuJU0XnXMzxp7rIBMEH2C-xPwvMonZkrceC_Z651CjKT8xInwnKdhGS2P28nYvg2KZKVq6zYO17AsVj2VeyrQT37L25AlvQJAPC-tLCH2AcXIwisbC4F51tRj_a6fO_SFp7h_aqZsFlxSm9PcSGWjnYUkna7g4YyNP-Fc7xqCLAQE5syW8-4LN9ZxbjvO1WcgYdOm4NWsQOnGOFQpv4ICz8EmYJWkwNOvLO9n0w_tSFLwCZgAi00cx0qr779yxFVEa5wje6wZpp1SqdCShCH3Uu1OVx_cmrsGEiRK2hw3xgoxkIwq-GSuxT2NnvhLfXBOPAiReWP9r-qLJSDGHsOqilLhkSvAe_iKIhQMH0avXhemEfBwZUVDbV35B5MjWULs3J0jHkw==) and LinkedIn\n(https://www.globenewswire.com/Tracker?data=kurM3RJ8zD9HXQLKgGE7TNHkqpMzCYDLvQ4qTnv9Q7PvrhjvdaEn6hTi4txf9gzwt8Q6WtK6uf6mXO5mk-EPr5u21Odz-BSGI2Jf-lVaW0HHXLhwuXzDAbdcCwxKQXHKphxYnjRe1m0tk6BJ0oCPvkZLDQpzxSdJjP3DObfQ7emXik667KROHlExLiom9JG1y4vcPQkqcDSwgUmxQsldPjhVcSkMS7oJ_4u6V6NJh72j-DZqi7h_xlg0fBhs0P7o).\n\nForward-Looking Statements \nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Such forward-looking\nstatements include, but are not limited to, those regarding: the reverse stock\nsplit and the timing thereof; the impact of the reverse stock split on\nstockholders and other securityholders; the potential for the company to\nincrease its share price and regain compliance with the Nasdaq continued\nlisting rules; the company’s belief regarding the potential benefits and\napplications of its drug candidates and programs, including the company’s\nplans to further advance its differentiating Immuno-STAT(® )platform and lead\nautoimmune asset, CUE-401; and the company’s business strategies, plans and\nprospects. Forward-looking statements, which are based on certain assumptions\nand describe the company’s future plans, strategies and expectations, can\ngenerally be identified by the use of forward-looking terms such as\n“believe,” “expect,” “may,” “will,” “should,” “would,”\n“could,” “seek,” “intend,” “plan,” “goal,” “project,”\n“estimate,” “anticipate,” “strategy,” “future,” “likely,”\n“promise” or other comparable terms, although not all forward-looking\nstatements contain these identifying words. All statements other than\nstatements of historical facts included in this press release regarding the\ncompany’s strategies, prospects, financial condition, operations, costs,\nplans and objectives are forward-looking statements. Important factors that\ncould cause the company’s actual results and financial condition to differ\nmaterially from those indicated in the forward-looking statements include,\namong others, the company’s ability to maintain its collaboration with\nImmunoScape; the company’s limited operating history, limited cash and a\nhistory of losses; the company’s ability to obtain adequate financing to\nfund its business operations in the near term and successfully remediate its\ncurrent “going concern” determination that it does not have sufficient\ncapital on hand to continue operations beyond the next twelve months; the\ncompany’s ability to achieve profitability; potential setbacks in the\ncompany’s research and development efforts including negative or\ninconclusive results from its preclinical studies or clinical trials or the\ncompany’s ability to replicate in later clinical trials positive results\nfound in preclinical studies and early-stage clinical trials of its product\ncandidates; serious and unexpected drug-related side effects or other safety\nissues experienced by participants in clinical trials; its ability to secure\nrequired U.S. Food and Drug Administration (FDA) or other governmental\napprovals for its product candidates and the breadth of any approved\nindication; adverse effects caused by public health pandemics, including\npossible effects on the company’s operations and clinical trials; delays and\nchanges in regulatory requirements, policy and guidelines including potential\ndelays in submitting required regulatory applications to the FDA; the\ncompany’s reliance on licensors, collaborators, contract research\norganizations, suppliers and other business partners; the company’s ability\nto obtain adequate financing to fund its business operations in the future and\nability to continue as a going concern; the company’s ability to maintain\nand enforce necessary patent and other intellectual property protection;\ncompetitive factors; general economic and market conditions and the other\nrisks and uncertainties described in the Risk Factors and Management's\nDiscussion and Analysis of Financial Condition and Results of Operations\nsections of the company’s most recently filed Annual Report on Form 10-K and\nany subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking\nstatement made by the company in this press release is based only on\ninformation currently available to the company and speaks only as of the date\non which it is made. The company undertakes no obligation to publicly update\nany forward-looking statement, whether written or oral, that may be made from\ntime to time, whether as a result of new information, future developments or\notherwise.\n\nInvestor Contact\nMarie Campinell\nSenior Director, Corporate Communications\nCue Biopharma, Inc.\nmcampinell@cuebio.com \n\nMedia Contact\nJonathan Pappas\nLifeSci Communications\njpappas@lifescicomms.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/10541379-34cc-4869-a26f-fd99feead42a)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-04-22T12:37:18.143470523Z","server_sent_at_ms":1776861438143},"received_at":"2026-04-22T12:37:18.196Z","source_url":null},"analysis":{"id":"3371","press_release_id":"4751","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["Reverse stock split implemented to regain Nasdaq compliance","High reverse split ratio (1-for-30) indicates significant prior share price depreciation"],"eventType":"other","narrative":"Cue Biopharma will implement a 1-for-30 reverse stock split effective April 23, 2026, reducing outstanding shares from approximately 97.7 million to roughly 3.3 million.\n\nThe primary goal of the split is to increase the per-share price to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.\n\nSplit-adjusted trading is expected to commence on April 24, 2026, under the existing ticker CUE with a new CUSIP number.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"Drastic 1-for-30 reverse split signals distress as Cue fights to maintain Nasdaq listing."},"keyFigures":{"customDimensions":{"reverse_split_ratio":"1-for-30","pre_split_shares_outstanding":"97.7 million","post_split_shares_outstanding":"3.3 million"}},"quotedText":"","namedEntities":{"people":[],"products":["CUE-401","Immuno-STAT"],"companies":[{"name":"Cue Biopharma, Inc.","ticker":"CUE"},{"name":"Nasdaq","relationship":"exchange"},{"name":"Computershare Trust Company, N.A.","relationship":"exchange agent"}],"dollarAmounts":[]},"materialImpact":{"score":4,"reasoning":"The 1-for-30 reverse stock split is a material restructuring event reducing outstanding shares by ~97% to satisfy Nasdaq listing requirements, signaling significant prior share price depreciation."},"tickerRelevance":{"others":[],"primary":"CUE"},"eventTypeSecondary":[]},"event_type":"other","event_type_secondary":null,"sentiment":"bearish","material_impact_score":4,"narrative":"Cue Biopharma will implement a 1-for-30 reverse stock split effective April 23, 2026, reducing outstanding shares from approximately 97.7 million to roughly 3.3 million.\n\nThe primary goal of the split is to increase the per-share price to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.\n\nSplit-adjusted trading is expected to commence on April 24, 2026, under the existing ticker CUE with a new CUSIP number.","key_figures":{"customDimensions":{"reverse_split_ratio":"1-for-30","pre_split_shares_outstanding":"97.7 million","post_split_shares_outstanding":"3.3 million"}},"named_entities":{"people":[],"products":["CUE-401","Immuno-STAT"],"companies":[{"name":"Cue Biopharma, Inc.","ticker":"CUE"},{"name":"Nasdaq","relationship":"exchange"},{"name":"Computershare Trust Company, N.A.","relationship":"exchange agent"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:2f2748f0fcc8c4f2","schema_hash":"sha256:ad96b863d7123008","created_at":"2026-04-22T16:26:55.367Z","global_importance":3,"audience_relevance":3,"importance_components":{"method":"backfill-heuristic","signals":{"bodyLong":false,"headlineTier1":false,"tickerCovered":false,"hadSignificance":false},"version":1,"computedAt":"2026-04-27T11:52:54.177Z"}},"durationMs":92326,"modelName":"glm-4.7"}}